Key Points
- CEO Eric Lefkofsky sold 166,250 shares at an average price of $46.38 on March 26 for $7,710,675, leaving him with 8,875,033 shares (a 1.84% reduction in his holding).
- Tempus shares were down about 6.4%, trading below their 50‑ and 200‑day moving averages and exhibiting high beta-driven volatility, signaling elevated short‑term downside risk.
- Meanwhile, institutions like Vanguard and ARK have been adding to positions, analysts maintain a consensus “Moderate Buy” rating with an average price target of $78.62, and Tempus announced collaborations such as with Daiichi Sankyo.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric Lefkofsky sold 166,250 shares of the business's stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $46.38, for a total value of $7,710,675.00. Following the transaction, the chief executive officer owned 8,875,033 shares in the company, valued at $411,624,030.54. The trade was a 1.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Tempus AI Stock Down 6.4%
TEM opened at $42.62 on Friday. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. The business has a 50 day simple moving average of $55.11 and a 200-day simple moving average of $69.65. The stock has a market capitalization of $7.62 billion, a P/E ratio of -30.23 and a beta of 5.29. Tempus AI, Inc. has a 12 month low of $36.22 and a 12 month high of $104.32.
Key Tempus AI News
Here are the key news stories impacting Tempus AI this week:
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of TEM. Vanguard Group Inc. lifted its stake in Tempus AI by 8.7% in the 4th quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company's stock valued at $605,772,000 after buying an additional 817,014 shares in the last quarter. ARK Investment Management LLC increased its position in Tempus AI by 5.3% during the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company's stock worth $446,275,000 after buying an additional 381,816 shares in the last quarter. GC Wealth Management RIA LLC acquired a new position in shares of Tempus AI in the fourth quarter worth $399,267,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Tempus AI by 1.2% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,504,823 shares of the company's stock worth $206,960,000 after acquiring an additional 41,728 shares during the last quarter. Finally, Amova Asset Management Americas Inc. lifted its position in shares of Tempus AI by 1.2% in the fourth quarter. Amova Asset Management Americas Inc. now owns 3,504,823 shares of the company's stock valued at $206,960,000 after acquiring an additional 41,728 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities research analysts have commented on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Tempus AI in a report on Thursday, January 22nd. HC Wainwright upped their price target on shares of Tempus AI from $89.00 to $95.00 and gave the stock a "buy" rating in a research note on Monday, March 9th. Stifel Nicolaus set a $60.00 price target on shares of Tempus AI in a report on Wednesday, February 25th. JPMorgan Chase & Co. reduced their price objective on shares of Tempus AI from $80.00 to $60.00 and set a "neutral" rating for the company in a research note on Wednesday, February 25th. Finally, Wall Street Zen downgraded shares of Tempus AI from a "hold" rating to a "sell" rating in a report on Saturday, February 28th. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Tempus AI presently has an average rating of "Moderate Buy" and an average price target of $78.62.
Get Our Latest Stock Report on TEM
Tempus AI Company Profile
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
